Research status of monoclonal antibody targeted therapy in children with severe bronchial asthma
10.3760/cma.j.cn101721-20201020-00010
- VernacularTitle:单克隆抗体靶向治疗儿童严重支气管哮喘的研究现状
- Author:
Zhuqing LI
1
;
Xiaohong WANG
Author Information
1. 山西医科大学，太原 030001
- Keywords:
Monoclonal antibody;
Omalizumab;
Mepolizumab;
Benralizumab;
Reslizumab;
Dupilumab;
Childhood asthma
- From:
Clinical Medicine of China
2021;37(4):381-384
- CountryChina
- Language:Chinese
-
Abstract:
Monoclonal antibody is a new treatment for severe asthma in children.It can selectively act on specific cytokines or pathways in the inflammatory cascade of asthma to block the inflammatory reaction, so as to reduce the number of acute attacks of asthma, reduce the dosage of drugs, and improve lung function.The main adverse reactions included injection site reaction and upper respiratory tract infection.At present, monoclonal antibodies for children include Omalizumab, Mepolizumab, Benralizumab, Reslizumab and Dupilumab.Although the efficacy of monoclonal antibody in children with asthma is obvious, its long-term effect and safety still need to be further confirmed by a large number of clinical studies.
